Breaking News

BARDA Extends Pfenex Contract

Increases funding for anthrax vaccine

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has modified its prime contract with Pfenex Inc. and exercised an option within the existing Pfenex contract from July 2010. The prime contract has been extended with increased funding of approximately $8 million to support the development of a next generation rPA-based anthrax vaccine using the Pfēnex Expression Technology platform. The total funding available is approx...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters